Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Exploratory, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability, and Efficacy of EMP-01 in Adult Participants With Social Anxiety Disorder

NCT06693609 is registered in ClinicalTrials.gov with atai Therapeutics, Inc. as lead sponsor.

NCT NCT06693609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06693609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Exploratory, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability, and Efficacy of EMP-01 in Adult Participants With Social Anxiety Disorder
Lead sponsor
atai Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 8, 2025
Completion date
December 10, 2025
Enrollment
70 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

social anxiety disorder